Antibacterial activity of extracellular compounds produced by a Pseudomonas strain against methicillin-resistant Staphylococcus aureus (MRSA) strains

Annals of Clinical Microbiology and Antimicrobials

Volumn 12, Issue 1, 2013, Pages

  Cardozo, Viviane F ^a   Oliveira, Admilton G ^a   Nishio, Erick K ^a   Perugini, Marcia R E ^a   Andrade, Célia G T J ^a   Silveira, Wanderley D ^b   Durán, Nelson ^b   Andrade, Galdino ^a   Kobayashi, Renata K T ^a   Nakazato, Gerson ^a  

^a UNIVERSITY OF LONDRINA   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Antibacterial activity; Methicillin resistant; Pseudomonas aeruginosa; Staphylococcus aureus

Indexed keywords

ACETIC ACID ETHYL ESTER; ANTIBIOTIC AGENT; DICHLOROMETHANE; MICROBIAL PRODUCTS NOT CLASSIFIED ELSEWHERE; ORGANOHALOGEN DERIVATIVE; PHENAZINE 1 CARBOXAMIDE; SILVER NANOPARTICLE; UNCLASSIFIED DRUG;

AGAR DIFFUSION; ANTIBACTERIAL ACTIVITY; ANTIBIOSIS; ARTICLE; BACTERIAL CELL WALL; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIAL VIABILITY; BACTERIUM ISOLATION; CELL STRUCTURE; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG ISOLATION; DRUG POTENTIATION; DRUG PURIFICATION; DRUG SCREENING; FUSARIUM OXYSPORUM; LIQUID CHROMATOGRAPHY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; SCANNING ELECTRON MICROSCOPY;

ACETATES; ANTI-BACTERIAL AGENTS; CELL WALL; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; FUSARIUM; HALOGENS; METAL NANOPARTICLES; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; METHYLENE CHLORIDE; MICROBIAL VIABILITY; PHENAZINES; PSEUDOMONAS AERUGINOSA; SILVER;

EID: 84879037294     PISSN: None     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/1476-0711-12-12     Document Type: Article

References (43)

1. Buke C, Armand-Lefevre L, Lolom I, Guerinot W, Deblangy C, Ruimy R, Andremont A, Lucet JC. Epidemiology of multidrug-resistant bacteria in patients with long hospital stays. Infect Control Hosp Epidemiol 2007, 28:1255-1260. 10.1086/522678, 17926276.
2. Strateva T, Ouzounova-Raykova V, Markova B, Todorova A, Marteva-Proevska Y, Mitov I. Problematic clinical isolates of Pseudomonas aeruginosa from the university hospitals in Sofia, Bulgaria: current status of antimicrobial resistance and prevailing resistance mechanisms. J Med Microbiol 2007, 56:956-963. 10.1099/jmm.0.46986-0, 17577062.
3. Stefani S, Varaldo PE. Epidemiology of methicillin-resistant staphylococci in Europe. Clin Microbiol Infect 2003, 9:1179-1186. 10.1111/j.1469-0691.2003.00698.x, 14686982.
4. Rodríguez-Noriega E, Seas C, Guzmán-Blanco M, Mejía C, Alvarez C, Bavestrello L, Zurita J, Labarca J, Luna CM, Salles MJ, Gotuzzo E. Evolution of methicillin-resistant Staphylococcus aureus clones in Latin America. Int J Infect Dis 2010, 14:e560-566. 10.1016/j.ijid.2009.08.018, 20047848.
5. Lee AS, Huttner B, Harbarth S. Control of methicillin-resistant Staphylococcus aureus. Infect Dis Clin North Am 2011, 25:155-179. 10.1016/j.idc.2010.11.002, 21315999.
6. Weese JS. Methicillin-resistant Staphylococcus aureus in animals. ILAR J 2010, 51:233-244. 10.1093/ilar.51.3.233, 21131724.
7. Smith TC, Pearson N. The emergence of Staphylococcus aureus ST398. Vector Borne Zoonotic Dis 2011, 11:327-339. 10.1089/vbz.2010.0072, 20925523.
8. Sader HS, Jones RN, Gales AC, Silva JB, Pignatari AC. SENTRY Participants Group (Latin America) SENTRY Antimicrobial Surveillance Program Report: Latin America and Brazilian results for 1997 through 2001. Braz J Infect Dis 2004, 8:25-79. 10.1590/S1413-86702004000100004, 15286878, SENTRY Participants Group (Latin America).
9. Oliveira G, Faria J, Levy C, Mamizuka EM. Characterization of the Brazilian endemic clone of methicillin-resistant Staphylococcus aureus (MRSA) from hospitals throughout Brazil. Braz J Infect Dis 2001, 5:163-170. 10.1590/S1413-86702001000400001, 11712960.
10. Karchmer TB, Durbin LJ, Simonton BM, Farr BM. Cost-effectiveness of active surveillance cultures and contact/droplet precautions for control of methicillin-resistant Staphylococcus aureus. J Hosp Infect 2002, 51:126-132. 10.1053/jhin.2002.1200, 12090800.
11. Laupland KB, Lee H, Gregson DB, Manns BJ. Cost of intensive care unit-acquired bloodstream infections. J Hosp Infect 2006, 63:124-132. 10.1016/j.jhin.2005.12.016, 16621137.
12. Crisóstomo MI, Westh H, Tomasz A, Chung M, Oliveira DC, de Lencastre H. The evolution of methicillin resistance in Staphylococcus aureus: similarity of genetic backgrounds in historically early methicillin-susceptible and -resistant isolates and contemporary epidemic clones. Proc Natl Acad Sci USA 2001, 98:9865-9870. 10.1073/pnas.161272898, 55544, 11481426.
13. O'Neill AJ. New antibacterial agents for treating infections caused by multi-drug resistant Gram-negative bacteria. Expert Opin Investig Drugs 2008, 17:297-302. 10.1517/13543784.17.3.297, 18321229.
14. Jamil M, Ul Haq I, Mirza B, Qayyum M. Isolation of antibacterial compounds from Quercus dilatata L. through bioassay guided fractionation. Ann Clin Microbiol Antimicrob 2012, 11(Jamil M, Ul Haq I, Mirza B, Qayyum M):11. 3416653, 22554280.
15. Choi JG, Kang OH, Chae HS, Obiang-Obounou B, Lee YS, Oh YC, Kim MS, Shin DW, Kim JA, Kim YH, Kwon DY. Antibacterial activity of Hylomecon hylomeconoides against methicillin-resistant Staphylococcus aureus. Appl Biochem Biotechnol 2010, 160:2467-2474. 10.1007/s12010-009-8698-5, 19578993.
16. Ifesan BO, Hamtasin C, Mahabusarakam W, Voravuthikunchai SP. Assessment of antistaphylococcal activity of partially purified fractions and pure compounds from Eleutherine americana. J Food Prot 2009, 72:354-359.
17. Zuo GY, Meng FY, Hao XY, Zhang YL, Wang GC. Xu GLAntibacterial alkaloids from chelidonium majus linn (papaveraceae) against clinical isolates of methicillin-resistant Staphylococcus aureus. J Pharm Sci 2008, 11:90-94.
18. Pereira EM, Machado TB, Leal ICR, Jesus DM, Damaso CRA, Pinto AV, de Marval MC, Kuster RM, dos Santos KRN. Tabebuia avellanedae naphthoquinones: activity against methicillin-resistant staphylococcal strains, cytotoxic activity and in vivo dermal irritability analysis. Ann Clin Microbiol Antimicrob 2006, 5:5. 10.1186/1476-0711-5-5, 1435768, 16553949.
19. Hashizume H, Igarashi M, Sawa R, Adachi H, Nishimura Y, Akamatsu Y. A new type of tripropeptin with anteiso-branched chain fatty acid from Lysobacter sp. BMK333-48F3. J Antibiot 2008, 61:577-582. 10.1038/ja.2008.78, 19160527.
20. Cazoto LL, Martins D, Ribeiro MG, Durán N, Nakazato G. Antibacterial activity of violacein against Staphylococcus aureus isolated from bovine mastitis. J Antibiot 2011, 64:395-397. 10.1038/ja.2011.13, 21364597.
21. Ding R, Wu XC, Qian CD, Teng Y, Li O, Zhan ZJ, Zhao YH. Isolation and identification of lipopeptide antibiotics from Paenibacillus elgii B69 with inhibitory activity against methicillin-resistant Staphylococcus aureus. J Microbiol 2011, 49:942-949. 10.1007/s12275-011-1153-7, 22203557.
22. Oliveira AG, Murate LS, Spago FR, Lopes LP, Beranger JPO, San Martin JAB, Nogueira MA, Mello JCP, Andrade CGTJ, Andrade G. Evaluation of the antibiotic activity of extracellular compounds produced by the Pseudomonas strain against the Xanthomonas citri pv. Citri 306 strain. Biol Control 2011, 56:125-131.
23. Kuroda M, Ohta T, Uchiyama I, Baba T, Yuzawa H, Kobayashi I, Cui L, Oguchi A, Aoki K, Nagai Y, Lian J, Ito T, Kanamori M, Matsumaru H, Maruyama A, Murakami H, Hosoyama A, Mizutani-Ui Y, Takahashi NK, Sawano T, Inoue R, Kaito C, Sekimizu K, Hirakawa H, Kuhara S, Goto S, Yabuzaki J, Kanehisa M, Yamashita A, Oshima K, Furuya K, Yoshino C, Shiba T, Hattori M, Ogasawara N, Hayashi H, Hiramatsu K. Whole genome sequencing of methicillin-resistant Staphylococcus aureus, the major hospital pathogen. Lancet 2001, 357:1225-1240. 10.1016/S0140-6736(00)04403-2, 11418146.
24. Soares MJ, Teixeira LA, Nunes MR, da Silva Carvalho MC, Ferreira-Carvalho BT, Figueiredo AM. Analysis of different molecular methods for typing methicillin-resistant Staphylococcus aureus isolates belonging to the Brazilian epidemic clone. J Med Microbiol 2001, 50:732-742.
25. Cury GG, Mobilon C, Stehling EG, Lancellotti M, Ramos Mde C, Martinez R, Brocchi M, Silveira WD. Molecular typing of methicillin-resistant Staphylococcus aureus (MRSA) strains isolated in two metropolitan areas of São Paulo State, Southeast Brazil. Braz J Infect Dis 2009, 13:165-169.
26. Rampazo LGL. Evaluation of the effect of biological agents and their products into the incidence of citrus canker lesions 2004, Londrina, Brasil: Master thesis, Universidade Estadual de.
27. Durán N, Marcato PD, Alves OL, de Souza GIH, Esposito E. Mechanistic aspects of biosynthesis of silver nanoparticles by several Fusarium oxysporum strains. J Nanobiotechnol 2005, 3:1-7.
28. CLSI (Clinical and Laboratory Standards Institute) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard, M07-A8 2011, Wayne, PA, USA: CLSI, 8, CLSI (Clinical and Laboratory Standards Institute).
29. Chin NX, Weitzman I, Della-Lata P. In vitro activity of fluvastatin, a cholesterol-lowering agent, and synergy with fluconazole and itraconazole against Candida species and Cryptococcus neoformans. Antimicrob Agents Chemother 1997, 41:850-852. 163809, 9087504.
30. Hafidh RR, Abdulamir AS, Vern LS, Abu Bakar F, Abas F, Jahanshiri F, Sekawi Z. Inhibition of growth of highly resistant bacterial and fungal pathogens by a natural product. Open Microbiol J 2011, 5:96-106. 10.2174/1874285801105010096, 3171003, 21915230.
31. Chung PY, Navaratnam P, Chung LY. Synergistic antimicrobial activity between pentacyclic triterpenoids and antibiotics against Staphylococcus aureus strains. Ann Clin Microbiol Antimicrob 2011, 10:25. 10.1186/1476-0711-10-25, 3127748, 21658242.
32. Mandal S, Manisha D, Saha K, Pal NK. In vitro antibacterial activity of three Indian spices against methicillin-resistant Staphylococcus aureus. Oman Med J 2011, 26:319-323. 10.5001/omj.2011.80, 3215437, 22125725.
33. Fukuda D, Haines AS, Song Z, Murphy AC, Hothersall J, Stephens ER, Gurney R, Cox RJ, Crosby J, Willis CL, Simpson TJ, Thomas CM. A natural plasmid uniquely encodes two biosynthetic pathways creating a potent anti-MRSA antibiotic. PLoS One 2011, 6:e18031. 10.1371/journal.pone.0018031, 3069032, 21483852.
34. Laursen JB, Nielsen J. Phenazine natural products: biosynthesis, synthetic analogues, and biological activity. Chem Rev 2004, 104:1663-1685. 10.1021/cr020473j, 15008629.
35. Mavrodi DV, Blankenfeldt W, Thomashow LS. Phenazine compounds in fluorescent Pseudomonas spp. biosynthesis and regulation. Ann Rev Phytopathol 2006, 44:417-445.
36. Jayatilake GS, Thornton MP, Leonard AC, Grimwade JE, Baker BJ. Metabolites from an Antarctic sponge-associated bacterium, Pseudomonas aeruginosa. J Nat Prod 1996, 59:293-296. 10.1021/np960095b, 8882433.
37. Choi EJ, Kwon HC, Ham J, Yang HO. 6-Hydroxymethyl-1-phenazine-carboxamide and 1,6-phenazinedimethanol from a marine bacterium, Brevibacterium sp. KMD 003, associated with marine purple vase sponge antibacterial phenazines from Brevibacterium sp. KMD 003. J Antibiot 2009, 62:621-624. 10.1038/ja.2009.92, 19798118.
38. Shanmugaiah Y, Mathivanan N, Varghese B. Purification, crystal structure and antimicrobial activity of phenazine-1-carboxamida produced by a growth-promoting biocontrol bacterium, Pseudomonas aeruginosa MML2212. J Appl Microbiol 2010, 108:703-711. 10.1111/j.1365-2672.2009.04466.x, 19778345.
39. Chin-A-Woeng TFD, Bloemberg GV, Lugtenberg BJ. Phenazine and their role in biocontrol by Pseudomonas bacteria. New Phytol 2003, 157:520-523.
40. Konaté K, Mavoungou JF, Lepengué AN, Aworet-Samseny RRR, Hilou A, Souza A, Dicko MH, M'Batchi B. Antibacterial activity against β- lactamase producing Methicillin and Ampicillin-resistants Staphylococcus aureus: fractional Inhibitory Concentration Index (FICI) determination. Ann Clin Microbiol Antimicrob 2012, 11:18. 10.1186/1476-0711-11-18, 3464800, 22716026.
41. Gribble GW. Commercial potential of naturally occurring halo-organics. Spec ChemMag 2003, 23:22-24.
42. Laus G. Biological activities of natural halogen compounds, of Studies in Natural Products Chemistry, Atta-ur-Rahman. Elsevier Science 2001, 757-809.
43. Jiang Z, Boyd KG, Mearns-Spragg A, Adams DR, Wright PC, Burgess JG. Two diketopiperazines and one halogenated phenol from cultures of the marine bacterium, Pseudoalteromonas luteoviolacea. Nat Prod Let. 2000, 14:435-440.